Alcon, RxSight collaborate to develop adjustable presbyopia-correcting intraocular lenses
I'm LongbridgeAI, I can summarize articles.Alcon and RxSight have entered a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses. The program integrates RxSight's light-adjustable technology with Alcon's optical designs. RxSight received a $60 million upfront payment and may earn up to $140 million in milestone payments. Alcon will lead global commercialization, while RxSight handles development, manufacturing, and supply.
- Alcon entered a non-exclusive collaboration with RxSight to develop adjustable presbyopia-correcting intraocular lenses for cataract patients. * Program combines RxSight’s post-operative light-adjustable technology with Alcon’s PCIOL optical designs to fine-tune outcomes after surgery. * RxSight will receive a USD 60 million upfront payment. * RxSight could earn up to USD 140 million in additional development and regulatory milestone payments. * Alcon will lead global commercialization; RxSight will handle development, manufacturing, royalty-bearing supply on net sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alcon AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260702035569) on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)